Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (33) 33
science & technology (33) 33
humans (25) 25
female (19) 19
cardiovascular system & cardiology (18) 18
male (17) 17
middle aged (17) 17
aged (16) 16
cardiac & cardiovascular systems (16) 16
abridged index medicus (15) 15
risk factors (12) 12
treatment outcome (9) 9
analysis (8) 8
care and treatment (8) 8
double-blind method (8) 8
atrial fibrillation (7) 7
health aspects (7) 7
peripheral vascular disease (7) 7
cardiovascular disease (6) 6
dosage and administration (6) 6
follow-up studies (6) 6
obesity (6) 6
prevention (6) 6
stroke (6) 6
ticagrelor (6) 6
adenosine - analogs & derivatives (5) 5
adult (5) 5
clinical trials (5) 5
general & internal medicine (5) 5
heart attacks (5) 5
heart failure (5) 5
hemorrhage - chemically induced (5) 5
internal medicine (5) 5
myocardial infarction (5) 5
myocardial infarction - drug therapy (5) 5
research (5) 5
usage (5) 5
adenosine - administration & dosage (4) 4
adenosine - adverse effects (4) 4
aged, 80 and over (4) 4
anticholesteremic agents - therapeutic use (4) 4
biological and medical sciences (4) 4
body mass index (4) 4
cardiac patients (4) 4
cardiovascular diseases (4) 4
coronary artery disease (4) 4
diabetes (4) 4
drug therapy (4) 4
exercise (4) 4
heart attack (4) 4
medicine, general & internal (4) 4
physical activity (4) 4
proprotein convertase 9 - antagonists & inhibitors (4) 4
purinergic p2y receptor antagonists - administration & dosage (4) 4
secondary prevention (4) 4
time factors (4) 4
warfarin (4) 4
acute coronary syndromes (3) 3
antibodies, monoclonal - adverse effects (3) 3
antibodies, monoclonal - therapeutic use (3) 3
anticholesteremic agents - adverse effects (3) 3
anticoagulants (3) 3
behavior (3) 3
beverages (3) 3
cardiology (3) 3
cardiovascular diseases - prevention & control (3) 3
child (3) 3
cholesterol, ldl - blood (3) 3
confidence intervals (3) 3
dapagliflozin (3) 3
diet (3) 3
disease progression (3) 3
drug administration schedule (3) 3
health behavior (3) 3
health promotion (3) 3
heart diseases (3) 3
hospitalization (3) 3
medical colleges (3) 3
mortality (3) 3
myocardial infarction - blood (3) 3
myocardial infarction - mortality (3) 3
myocardial infarction - prevention & control (3) 3
purinergic p2y receptor antagonists - adverse effects (3) 3
pyridines - adverse effects (3) 3
stroke - prevention & control (3) 3
type 2 diabetes (3) 3
adenosine - pharmacokinetics (2) 2
alzheimer disease - cerebrospinal fluid (2) 2
alzheimer's disease (2) 2
amyloid (2) 2
arteriosclerosis (2) 2
aspirin (2) 2
atrial fibrillation - complications (2) 2
biochemistry & molecular biology (2) 2
biomarkers - blood (2) 2
blood glucose - metabolism (2) 2
blood platelets - drug effects (2) 2
body weight (2) 2
cardiac and cardiovascular systems (2) 2
cardiovascular (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
by Ruff, Christian T, Dr and Giugliano, Robert P, MD and Braunwald, Eugene, Prof and Morrow, David A, MD and Murphy, Sabina A, MPH and Kuder, Julia F, MA and Deenadayalu, Naveen, MPH and Jarolim, Petr, MD and Betcher, Joshua, PhD and Shi, Minggao, PhD and Brown, Karen, PhD and Patel, Indravadan, MD and Mercuri, Michele, MD and Antman, Elliott M, Prof
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9984, pp. 2288 - 2295
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Stroke - prevention & control | Pyridines - administration & dosage | Double-Blind Method | Atrial Fibrillation - drug therapy | Humans | Atrial Fibrillation - complications | Pyridines - pharmacokinetics | Factor Xa Inhibitors - pharmacokinetics | Thiazoles - administration & dosage | Treatment Outcome | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Factor Xa Inhibitors - administration & dosage | Pyridines - adverse effects | Factor Xa Inhibitors - adverse effects | Hemorrhage - chemically induced | Clinical trials | Warfarin | Analysis | Atrial fibrillation | Anticoagulants | Cardiac arrhythmia | Stroke | Drug dosages | Medical treatment | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
by Wiviott, Stephen D and Raz, Itamar and Bonaca, Marc P and Mosenzon, Ofri and Kato, Eri T and Cahn, Avivit and Silverman, Michael G and Zelniker, Thomas A and Kuder, Julia F and Murphy, Sabina A and Bhatt, Deepak L and Leiter, Lawrence A and McGuire, Darren K and Wilding, John P.H and Ruff, Christian T and Gause-Nilsson, Ingrid A.M and Fredriksson, Martin and Johansson, Peter A and Langkilde, Anna-Maria and Sabatine, Marc S and DECLARE-TIMI 58 Investigators and DECLARE–TIMI 58 Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England journal of medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus | Life Sciences | Food and Nutrition | Animal biology | Cellular Biology | Pharmaceutical sciences | Cardiovascular Diseases | drug therapy | Benzhydryl Compounds | complications | Sodium-Glucose Transporter 2 Inhibitors | Hospitalization | prevention & control | Klinisk medicin | Diabetes Mellitus | etiology | Clinical Medicine | epidemiology | statistics & numerical data | adverse effects | mortality | Type 2 | Heart Failure | therapeutic use | Glucosides
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
by Storey, Robert F., MD, DM and Angiolillo, Dominick J., MD and Bonaca, Marc P., MD, MPH and Thomas, Mark R., MD and Judge, Heather M., PhD and Rollini, Fabiana, MD and Franchi, Francesco, MD and Ahsan, Arif J., MD and Bhatt, Deepak L., MD, MPH and Kuder, Julia F., MA and Steg, Philippe Gabriel, MD and Cohen, Marc, MD and Muthusamy, Rangasamy, MD and Braunwald, Eugene, MD and Sabatine, Marc S., MD, MPH
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 10, pp. 1145 - 1154
Cardiovascular | Internal Medicine | coronary artery disease | P2Y12 receptor | aspirin | Key Words aspirin | receptor | P2Y | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Myocardial Infarction - blood | Adenosine - pharmacokinetics | Purinergic P2Y Receptor Antagonists - administration & dosage | Follow-Up Studies | Humans | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Treatment Outcome | Adenosine - administration & dosage | Dose-Response Relationship, Drug | Myocardial Infarction - drug therapy | Time Factors | Adenosine - analogs & derivatives | Platelet Aggregation - drug effects | Blood Platelets - drug effects | Prevention | Medical colleges | Aspirin | Hospitals | Cardiac patients | Research institutes | Cardiology | Heart diseases | Confidence intervals | Adenosine | Phosphorylation | Heart attacks | Blood platelets | Coronary vessels | Cardiovascular disease | Acute coronary syndromes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
by Sabatine, Marc S and Giugliano, Robert P and Keech, Anthony C and Honarpour, Narimon and Wiviott, Stephen D and Murphy, Sabina A and Kuder, Julia F and Wang, Huei and Liu, Thomas and Wasserman, Scott M and Sever, Peter S and Pedersen, Terje R and FOURIER Steering Comm Investigator and FOURIER Steering Committee and Investigators
The New England journal of medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 18, pp. 1713 - 1722
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Atherosclerosis - drug therapy | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Incidence | Cardiovascular Diseases - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Least-Squares Analysis | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Drug Therapy, Combination | Prevention | Treatment outcome | Cardiovascular diseases | Drug therapy | Analysis | Stroke | Monoclonal antibodies | Cardiovascular disease | Patients | Drug dosages | Low density lipoprotein | Statins | Clinical outcomes | Cholesterol | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial
by O’Donoghue, Michelle L and Glaser, Ruchira and Cavender, Matthew A and Aylward, Philip E and Bonaca, Marc P and Budaj, Andrzej and Davies, Richard Y and Dellborg, Mikael and Fox, Keith A. A and Gutierrez, Jorge Antonio T and Hamm, Christian and Kiss, Robert G and Kovar, František and Kuder, Julia F and Im, Kyung Ah and Lepore, John J and Lopez-Sendon, Jose L and Ophuis, Ton Oude and Parkhomenko, Alexandr and Shannon, Jennifer B and Spinar, Jindrich and Tanguay, Jean-Francois and Ruda, Mikhail and Steg, P. Gabriel and Theroux, Pierre and Wiviott, Stephen D and Laws, Ian and Sabatine, Marc S and Morrow, David A and LATITUDE-TIMI 60 Investigators and for the LATITUDE-TIMI 60 Investigators and Sahlgrenska akademin and Institute of Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för medicin
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1591 - 1599
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Male | Secondary Prevention | Cyclopropanes - adverse effects | Protein Kinase Inhibitors - adverse effects | Cyclopropanes - therapeutic use | Pyridines - adverse effects | Treatment Failure | Female | C-Reactive Protein - analysis | Myocardial Infarction - enzymology | Pyridines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Myocardial Ischemia - prevention & control | Hospitalization | Myocardial Revascularization | Algorithms | Myocardial Infarction - drug therapy | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Aged | Myocardial Ischemia - surgery | Clinical trials | Care and treatment | Usage | Dosage and administration | Extracellular signal-regulated kinases | Heart attack | Patient safety | Inhibitor drugs | Heart attacks | Clinical outcomes | Index Medicus | Abridged Index Medicus | Pyridines/adverse effects/therapeutic use | Cyclopropanes/adverse effects/therapeutic use | C-Reactive Protein/analysis | Klinisk medicin | Clinical Medicine | p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors | Myocardial Ischemia/prevention & control/surgery | Protein Kinase Inhibitors/adverse effects/therapeutic use | Myocardial Infarction/drug therapy/enzymology/mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
by Bonaca, Marc P and Bhatt, Deepak L and Storey, Robert F and Steg, Ph. Gabriel and Cohen, Marc and Kuder, Julia and Goodrich, Erica and Nicolau, José C and Parkhomenko, Alexander and López-Sendón, José and Dellborg, Mikael and Dalby, Anthony and Špinar, Jindřich and Aylward, Philip and Corbalán, Ramón and Abola, Maria Teresa B and Jensen, Eva C and Held, Peter and Braunwald, Eugene and Sabatine, Marc S and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2016, Volume 67, Issue 23, pp. 2719 - 2728
peripheral arterial disease | ticagrelor | major adverse cardiovascular events | major adverse limb events | acute limb ischemia | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Myocardial Infarction - epidemiology | Purinergic P2Y Receptor Antagonists - administration & dosage | Vascular Grafting - statistics & numerical data | Humans | Middle Aged | Male | Secondary Prevention | Ischemia - prevention & control | Aspirin - administration & dosage | Dose-Response Relationship, Drug | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Female | Stroke - epidemiology | Lower Extremity - surgery | Drug Therapy, Combination | Stroke - prevention & control | Hemorrhage - epidemiology | Ischemia - epidemiology | Adenosine - administration & dosage | Peripheral Arterial Disease - epidemiology | Adenosine - analogs & derivatives | Ischemia - surgery | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Lower Extremity - blood supply | Prevention | Medical colleges | Care and treatment | Ischemia | Cardiology | Heart attack | Heart failure | Anticoagulants | Aspirin | Stroke | Heart attacks | Heart surgery | Mortality | Cardiovascular disease | Confidence intervals | Disease prevention | Coronary vessels | Amputation | Chronic obstructive pulmonary disease | Diabetes | Index Medicus | Abridged Index Medicus | Kardiologi | Cardiac and Cardiovascular Systems | acute limb ischemia; major adverse cardiovascular events; major adverse limb events; peripheral arterial disease; ticagrelor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Healthy-lifestyle behaviors associated with overweight and obesity in US rural children
by Tovar, Alison and Chui, Kenneth and Hyatt, Raymond R and Kuder, Julia and Kraak, Vivica I and Choumenkovitch, Silvina F and Hastings, Alia and Bloom, Julia and Economos, Christina D
BMC pediatrics, ISSN 1471-2431, 07/2012, Volume 12, Issue 1, pp. 102 - 102
Rural | Obesity | Diet | Physical activity | Vulnerable populations | Healthy lifestyle behaviors | Children | Life Sciences & Biomedicine | Pediatrics | Science & Technology | Life Style | Prevalence | Cross-Sectional Studies | California - epidemiology | Humans | Mississippi - epidemiology | Logistic Models | Male | Health Behavior | Rural Health | Case-Control Studies | Exercise | South Carolina - epidemiology | Health Surveys | Overweight - epidemiology | Overweight - etiology | Obesity - epidemiology | Kentucky - epidemiology | Female | Obesity - etiology | Surveys and Questionnaires | Child | Government aid | Analysis | Obesity in children | Behavior | Beverages | Health aspects | Low income groups | Nutrition research | Statistical analysis | Nutrition | Families & family life | Rural schools | Population density | Manuscripts | Children & youth | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
by Boriani, Giuseppe and Ruff, Christian T and Kuder, Julia F and Shi, Minggao and Lanz, Hans J and Rutman, Howard and Mercuri, Michele F and Antman, Elliott M and Braunwald, Eugene and Giugliano, Robert P
European heart journal, ISSN 0195-668X, 05/2019, Volume 40, Issue 19, pp. 1541 - 1550
Obesity | Stroke | Warfarin | Edoxaban | Atrial fibrillation | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights